Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production.

Zanthobungeanine has anti-inflammatory activity, it shows moderate NO production inhibitory activity with an IC50 value of 37.26 mg /L.It shows obviously inhibitoryactivity to platelet aggregation caused by platelet-activating factor (PAF). Zanthobungeanine shows the inhibitory action on the development of A549 cell only in high concentration and has no antipersonnel effect on A549 cell.

Poricoic acid B shows inhibitory activity against TPA-induced ear inflammatory oedema.